World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
81
Citations
29551
World Ranking
16474
National Ranking
8280

Biology and Biochemistry

D-Index
81
Citations
29475
World Ranking
3817
National Ranking
1889

Paul E. Sax publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Paul E. Sax sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 413 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 848 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 949 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 840 scientists 207–216 publications: 733 scientists 217–226 publications: 708 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 417 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 196 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 59 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 636 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Paul E. Sax D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Paul E. Sax sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 316 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 899 scientists 52–53 D-Index: 1,025 scientists 54–55 D-Index: 1,149 scientists 56–57 D-Index: 1,235 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,162 scientists 62–63 D-Index: 1,130 scientists 64–65 D-Index: 1,031 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 714 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 71 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 81 D-Index — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Overview

Paul E. Sax is affiliated with Brigham and Women's Hospital in the United States. Their research primarily focuses on the field of Medicine, with a strong emphasis on Infectious Diseases and related subfields such as Virology, Emergency Medicine, Epidemiology, and Neurology.

The scientist has contributed extensively to topics related to HIV/AIDS and COVID-19. Key areas of work cover:

  • HIV/AIDS drug development and treatment
  • HIV Research and Treatment
  • HIV-related health complications and treatments
  • HIV/AIDS Research and Interventions
  • COVID-19 Clinical Research Studies
  • Long-Term Effects of COVID-19
  • SARS-CoV-2 and COVID-19 Research

Paul E. Sax's recent scholarly publications include:

  • "Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors," 2020, Annals of Internal Medicine
  • "Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults," 2022, JAMA
  • "Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults," 2020, JAMA
  • "Characteristics, Comorbidities, and Outcomes in a Multicenter Registry of Patients With Human Immunodeficiency Virus and Coronavirus Disease 2019," 2020, Clinical Infectious Diseases
  • "Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial," 2021, The Lancet

Frequent co-authors collaborating with Paul E. Sax include:

  • David A. Wohl
  • Essy Mozaffari
  • Chloe Orkin
  • Joseph J. Eron
  • Eric S. Daar

Over the course of their career, Paul E. Sax has published extensively in prominent infectious disease and medical journals. The most common venues for their work include:

  • Clinical Infectious Diseases
  • Open Forum Infectious Diseases
  • UNC Libraries
  • JAMA
  • The Lancet HIV

Best Publications

  • Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

    Eric S. Rosenberg;James M. Billingsley;Angela M. Caliendo;Steven L. Boswell

  • The major genetic determinants of HIV-1 control affect HLA class I peptide presentation

    Pereyra F;Jia X;McLaren Pj

  • Metabolic Abnormalities and Cardiovascular Disease Risk Factors in Adults with Human Immunodeficiency Virus Infection and Lipodystrophy

    Colleen Hadigan;James B. Meigs;Colleen Corcoran;Petra Rietschel

  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society–USA Panel

    Huldrych F. Günthard;Michael S. Saag;Constance A. Benson;Carlos del Rio

  • Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors.

    Eric A. Meyerowitz;Aaron Richterman;Rajesh T. Gandhi;Paul E. Sax

  • Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

    Paul E Sax;David Wohl;Michael T Yin;Frank Post

  • The Survival Benefits of AIDS Treatment in the United States

    Rochelle P. Walensky;Rochelle P. Walensky;A. David Paltiel;Elena Losina;Lauren M. Mercincavage

  • Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials

    Paul E. Sax;Kristine M. Erlandson;Jordan E. Lake;Grace A. McComsey

  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel

    Michael S. Saag;Constance A. Benson;Rajesh T. Gandhi;Jennifer F. Hoy

  • Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

    Grace A. McComsey;Douglas Kitch;Eric S. Daar;Camlin Tierney

  • Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

    Paul E. Sax;Edwin DeJesus;Anthony Mills;Andrew Zolopa

  • The lifetime cost of current human immunodeficiency virus care in the United States.

    Bruce R. Schackman;Kelly A. Gebo;Rochelle P. Walensky;Elena Losina

  • Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1

    Susanna Naggie;Curtis Cooper;Michael Saag;Kimberly Workowski

  • Cellular Immune Responses and Viral Diversity in Individuals Treated during Acute and Early HIV-1 Infection

    Marcus Altfeld;Eric S. Rosenberg;Raj Shankarappa;Joia S. Mukherjee

  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel.

    Michael S. Saag;Rajesh T. Gandhi;Jennifer F. Hoy;Raphael J. Landovitz

  • Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy

    Judith S. Currier;Jens D. Lundgren;Andrew Carr;Daniel Klein

  • Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial.

    Colleen Hadigan;Colleen Corcoran;Nesli Basgoz;Benjamin Davis

  • Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials

    Jean B. Nachega;Jean Jacques Parienti;Olalekan A. Uthman;Olalekan A. Uthman;Olalekan A. Uthman;Robert Gross

  • Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

    Paul E. Sax;Camlin Tierney;Ann C. Collier;Margaret A. Fischl

  • Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

    Antonella Castagna;Franco Maggiolo;Giovanni Penco;David Wright

Frequent Co-Authors

Kenneth A. Freedberg
Kenneth A. Freedberg Harvard University
Rochelle P. Walensky
Rochelle P. Walensky Harvard University
Eric S. Daar
Eric S. Daar Lundquist Institute
Elena Losina
Elena Losina Brigham and Women's Hospital
Edwin DeJesus
Edwin DeJesus Hanover University of Applied Sciences and Arts
Milton C. Weinstein
Milton C. Weinstein Harvard University
Joseph J. Eron
Joseph J. Eron University of North Carolina at Chapel Hill
Grace A. McComsey
Grace A. McComsey Case Western Reserve University
Graeme Moyle
Graeme Moyle Chelsea and Westminster Hospital NHS Foundation Trust
Chloe Orkin
Chloe Orkin Queen Mary University of London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

With a strong foundation in Biology and Biochemistry, students can explore a variety of related online degrees that open doors to rewarding careers in science and healthcare. Flexible learning options make it easier to upskill or specialize while accommodating work or family commitments.

For those interested in leadership roles within healthcare organizations, a phd in healthcare administration online offers advanced training in management and policy. Aspiring pharmacists can gain clinical and research expertise through reputable pharmd online programs designed to prepare students for licensure and practice.

If your interests lean toward fitness, sports, or health promotion, consider the best online exercise science degree to learn about human movement, physiology, and wellness. Alternatively, an online kinesiology bachelor's degree is ideal for students who want to work in rehabilitation, athletic training, or physical therapy.

Each of these online programs supports career growth and specialization, helping graduates remain competitive in the evolving fields of biology and health sciences.

Best Scientists Citing Paul E. Sax

Trending Scientists

Recently Published Articles